PL3138555T3 - Kompozycja liposomowa i sposób jej wytwarzania - Google Patents

Kompozycja liposomowa i sposób jej wytwarzania

Info

Publication number
PL3138555T3
PL3138555T3 PL15785362T PL15785362T PL3138555T3 PL 3138555 T3 PL3138555 T3 PL 3138555T3 PL 15785362 T PL15785362 T PL 15785362T PL 15785362 T PL15785362 T PL 15785362T PL 3138555 T3 PL3138555 T3 PL 3138555T3
Authority
PL
Poland
Prior art keywords
production
liposomal composition
liposomal
composition
Prior art date
Application number
PL15785362T
Other languages
English (en)
Inventor
Makoto Ono
Kohei Ono
Takeshi Matsumoto
Mikinaga Mori
Original Assignee
Fujifilm Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujifilm Corporation filed Critical Fujifilm Corporation
Publication of PL3138555T3 publication Critical patent/PL3138555T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • B01J13/20—After-treatment of capsule walls, e.g. hardening
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
PL15785362T 2014-04-30 2015-04-30 Kompozycja liposomowa i sposób jej wytwarzania PL3138555T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014094140 2014-04-30
EP15785362.3A EP3138555B1 (en) 2014-04-30 2015-04-30 Liposome composition and production method therefor
PCT/JP2015/062983 WO2015166986A1 (ja) 2014-04-30 2015-04-30 リポソーム組成物及びその製造方法

Publications (1)

Publication Number Publication Date
PL3138555T3 true PL3138555T3 (pl) 2021-04-06

Family

ID=54358710

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15785362T PL3138555T3 (pl) 2014-04-30 2015-04-30 Kompozycja liposomowa i sposób jej wytwarzania

Country Status (15)

Country Link
US (3) US10391057B2 (pl)
EP (1) EP3138555B1 (pl)
JP (1) JP6251385B2 (pl)
CY (1) CY1123731T1 (pl)
DK (1) DK3138555T3 (pl)
ES (1) ES2836772T3 (pl)
HR (1) HRP20202030T1 (pl)
HU (1) HUE052968T2 (pl)
LT (1) LT3138555T (pl)
PL (1) PL3138555T3 (pl)
PT (1) PT3138555T (pl)
RS (1) RS61273B1 (pl)
SI (1) SI3138555T1 (pl)
SM (1) SMT202000687T1 (pl)
WO (1) WO2015166986A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015166985A1 (ja) * 2014-04-30 2015-11-05 富士フイルム株式会社 リポソーム組成物及びその製造方法
WO2015166986A1 (ja) * 2014-04-30 2015-11-05 富士フイルム株式会社 リポソーム組成物及びその製造方法
JP6564873B2 (ja) * 2015-11-02 2019-08-21 富士フイルム株式会社 リポソーム組成物およびその製造方法
TWI882475B (zh) 2018-06-20 2025-05-01 日商富士軟片股份有限公司 包含內含吉西他濱之脂質體組成物及免疫檢查點抑制劑之組合醫藥
HUE069834T2 (hu) 2020-04-03 2025-04-28 Fujifilm Corp Tumorellenes szer
JP7657627B2 (ja) * 2021-03-25 2025-04-07 富士フイルム株式会社 化粧料用リポソーム組成物

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US4970074A (en) 1987-06-29 1990-11-13 Abbott Laboratories Fluorophores for encapsulation into liposomes
US5328678A (en) 1987-11-04 1994-07-12 Vestar, Inc. Composition and method of use for liposome encapsulated compounds for neutron capture tumor therapy
DE68901733T2 (de) 1988-03-04 1993-03-25 Takeda Chemical Industries Ltd Liposom-zusammensetzung.
JP2931981B2 (ja) 1988-03-04 1999-08-09 武田薬品工業株式会社 リポソーム製剤およびその製造法
US5049392A (en) 1989-01-18 1991-09-17 The Liposome Company, Inc. Osmotically dependent vesicles
US5227170A (en) 1989-06-22 1993-07-13 Vestar, Inc. Encapsulation process
IS1685B (is) 1990-12-11 1998-02-24 Bracco International B.V. Aðferð við að búa til fitukúlur (liposomes) sem eru gæddar auknum hæfileika til að draga í sig og halda í sér aðskotaefnum
JPH069374A (ja) * 1992-04-07 1994-01-18 Banyu Pharmaceut Co Ltd リポソ−ム製剤およびその製造法
CA2093381A1 (en) * 1992-04-07 1993-10-08 Hideyuki Sawahara Liposome formulation and process for production thereof
ES2115343T3 (es) * 1993-11-05 1998-06-16 Amgen Inc Metodo de preparacion de liposomas y encapsulacion de material.
US5540935A (en) 1993-12-06 1996-07-30 Nof Corporation Reactive vesicle and functional substance-fixed vesicle
US6261597B1 (en) 1995-08-31 2001-07-17 Seymour J. Kurtz Method for treating periodontal disease
CA2241247C (en) * 1995-12-15 2004-01-20 G. Dennis Sprott Archaeosomes, archaeosomes containing coenzyme q10, and other types of liposomes containing coenzyme q10 as adjuvants and as delivery vehicles
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
CA2467064C (en) * 2001-11-13 2011-02-08 Murray Webb Lipid carrier compositions with enhanced blood stability
WO2004017944A1 (en) * 2002-08-23 2004-03-04 Neopharm, Inc. Liposomal gemcitabine compositions for better drug delivery
EP1585504A4 (en) 2002-11-06 2009-07-15 Azaya Therapeutics Inc Protein stabilized liposomal formulations of pharmaceutical active ingredients
US20060240090A1 (en) 2003-04-02 2006-10-26 Lawrence Mayer Combination compositions of camptothecins and fluoropyrimidines
EP1643971A2 (en) 2003-05-22 2006-04-12 Neopharm, Inc. Liposomal formulations comprising a combination of two or more active agents
WO2005021012A1 (ja) 2003-08-29 2005-03-10 Terumo Kabushiki Kaisha ゲムシタビン封入薬剤担体
CA2566007C (en) 2004-05-03 2013-09-24 Hermes Biosciences, Inc. Drug delivery liposomes containing anionic polyols or anionic sugars
JP2008501652A (ja) 2004-06-03 2008-01-24 エフ．ホフマン−ラ　ロシュ　アーゲー ゲムシタビン及びｅｇｆｒインヒビターによる治療
WO2006032136A1 (en) * 2004-09-20 2006-03-30 British Columbia Cancer Agency Branch Free or liposomal gemcitabine alone or in combination with free or liposomal idarubicin
MX2007013978A (es) 2005-05-09 2008-02-22 Ono Pharmaceutical Co Anticuerpos monoclonales humanos a muerte programada 1 (pd-1) y metodos para tratamiento de cancer utilizando anticuerpos anti-pd-1 solos o en combinacion con otros inmunoterapeuticos.
JPWO2006137377A1 (ja) * 2005-06-22 2009-01-22 独立行政法人理化学研究所 神経再生促進剤
TW200726485A (en) * 2005-07-01 2007-07-16 Alza Corp Liposomal delivery vehicle for hydrophobic drugs
US20070178147A1 (en) 2005-12-08 2007-08-02 Desai Narendra R Liposomal compositions
US8119156B2 (en) 2006-10-24 2012-02-21 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
JP5080779B2 (ja) 2006-10-25 2012-11-21 テルモ株式会社 リポソーム製剤の製造方法
CN101209243B (zh) 2006-12-29 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 一种脂质体药物及其制备方法
CN100496609C (zh) 2006-12-30 2009-06-10 上海艾力斯医药科技有限公司 一种稳定的脂质体组合物
EP2197917A1 (en) 2007-09-28 2010-06-23 Universitätsspital Basel Immunoliposomes for treatment of cancer
NZ588749A (en) 2008-04-17 2012-06-29 Univ Johns Hopkins On01910. na enhances chemotherapeutic agent activity in drug-resistant tumors
US8231895B2 (en) 2008-05-22 2012-07-31 Universidade De Coimbra Targeted delivery to human diseases and disorders
CN101444485B (zh) * 2008-12-25 2011-11-23 中国医药集团总公司四川抗菌素工业研究所 吉西他滨脂质体及其制备方法
PL387296A1 (pl) * 2009-02-17 2010-08-30 Instytut Farmaceutyczny Sposób aktywnego zamykania amfifilowych substancji czynnych w strukturach liposomowych
DK177529B1 (en) 2009-10-23 2013-09-08 Bio Bedst Aps Liposomes with improved storage stability
KR20120086729A (ko) 2009-11-20 2012-08-03 클라비스 파마 에이에스에이 젬시타빈 유도체의 비경구적 제제
PL2508170T3 (pl) 2009-12-03 2015-12-31 Jiangsu Hengrui Medicine Co Liposom zawierający irynotekan lub jego chlorowodorek i metoda jego otrzymywania
JP2013126953A (ja) * 2010-03-31 2013-06-27 Terumo Corp リポソーム製剤の製造方法
CN101822669B (zh) 2010-04-23 2012-06-13 海南美兰史克制药有限公司 一种阿莫西林钠舒巴坦钠药物组合物脂质体注射剂
EP2394640A1 (en) 2010-05-21 2011-12-14 MediGene AG Improved liposomal formulations of lipophilic compounds
CN101926779A (zh) 2010-08-19 2010-12-29 苏州特瑞药业有限公司 一种吉西他滨固体脂质纳米粒及其制备方法与用途
BR112013024663A2 (pt) 2011-03-25 2016-12-20 Terumo Corp composição de lipossomas de liberação controlada de longa duração e método para produção da mesma
JP5853453B2 (ja) 2011-07-15 2016-02-09 コニカミノルタ株式会社 リポソームを製造する方法
US8987224B2 (en) 2011-08-05 2015-03-24 Baylor College Of Medicine MicroRNA-198 as a tumor suppressor in pancreatic cancer
CA2852564A1 (en) 2011-10-31 2013-05-10 Mallinckrodt Llc Combinational liposome compositions for cancer therapy
EP2604253A1 (en) 2011-12-13 2013-06-19 Otto Glatter Water-in-oil emulsions and methods for their preparation
KR101626703B1 (ko) 2012-04-04 2016-06-02 할로자임, 아이엔씨 항-히알루로난 제제 및 종양-표적 탁산을 이용한 병용 치료
CN102784107B (zh) * 2012-05-17 2015-04-22 江苏豪森药业股份有限公司 一种吉西他滨或其盐脂质体及其制备方法和用途
CN102716089B (zh) * 2012-06-29 2013-12-11 海南灵康制药有限公司 一种盐酸吉西他滨脂质体注射剂
KR20150095809A (ko) 2012-12-12 2015-08-21 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 암 치료용 조성물 및 방법
CA2936345A1 (en) 2013-01-14 2014-07-17 Chemo-Enhanced Llc Compositions and methods for treating cancer
EP4378461A3 (en) 2013-03-05 2024-09-11 The Regents of University of California Lipid bilayer coated mesoporous silica nanoparticles with a high loading capacity for one or more anticancer agents
EA201690746A1 (ru) 2013-10-25 2016-12-30 Фармасайкликс Элэлси Лечение с применением ингибиторов тирозинкиназы брутона и иммунотерапии
WO2015166985A1 (ja) * 2014-04-30 2015-11-05 富士フイルム株式会社 リポソーム組成物及びその製造方法
WO2015166988A1 (ja) 2014-04-30 2015-11-05 富士フイルム株式会社 リポソームの製造方法
JP6276847B2 (ja) 2014-04-30 2018-02-07 富士フイルム株式会社 リポソーム組成物及びその製造方法
WO2015166986A1 (ja) * 2014-04-30 2015-11-05 富士フイルム株式会社 リポソーム組成物及びその製造方法
EP3142697A1 (en) 2014-05-15 2017-03-22 Bristol-Myers Squibb Company Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
WO2016172494A2 (en) 2015-04-23 2016-10-27 The Johns Hopkins University Combination of immunotherapy with local chemotherapy for the treatment of malignancies
HK1255916A1 (zh) 2015-06-29 2019-09-06 Syndax Pharmaceuticals Inc. 组织蛋白去乙醯酶抑制剂与免疫检查点抑制抗体的合并癌症治疗
CN105012966B (zh) 2015-07-01 2018-11-02 南通厚元生物科技有限公司 吉西他滨-磷脂复合物的制备方法及其应用
JP6564873B2 (ja) 2015-11-02 2019-08-21 富士フイルム株式会社 リポソーム組成物およびその製造方法
MA43183A (fr) 2015-11-02 2018-09-12 Fujifilm Corp Agent thérapeutique antitumoral contenant une composition liposomale à base de gemcitabine et kit associé
CN106955354B (zh) 2016-01-11 2020-06-19 中国科学院分子细胞科学卓越创新中心 用于肿瘤免疫治疗的联合用药物组合
US10940112B2 (en) 2016-05-04 2021-03-09 L.E.A.F. Holdings Group Llc Targeted liposomal gemcitabine compositions and methods thereof
CN110072540B (zh) 2016-10-12 2023-06-02 得克萨斯州大学系统董事会 用于tusc2免疫治疗的方法和组合物
JP2019536805A (ja) 2016-12-05 2019-12-19 ジー１、セラピューティクス、インコーポレイテッドＧ１ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 化学療法計画中の免疫応答の保護

Also Published As

Publication number Publication date
HRP20202030T1 (hr) 2021-02-19
JP6251385B2 (ja) 2017-12-20
US10391057B2 (en) 2019-08-27
EP3138555A1 (en) 2017-03-08
US20210100745A1 (en) 2021-04-08
US20170042811A1 (en) 2017-02-16
US10898435B2 (en) 2021-01-26
PT3138555T (pt) 2020-12-15
EP3138555A4 (en) 2017-03-08
US11684575B2 (en) 2023-06-27
SI3138555T1 (sl) 2021-06-30
CY1123731T1 (el) 2022-05-27
EP3138555B1 (en) 2020-10-28
SMT202000687T1 (it) 2021-01-05
ES2836772T3 (es) 2021-06-28
HUE052968T2 (hu) 2021-05-28
LT3138555T (lt) 2021-03-25
US20190336447A1 (en) 2019-11-07
JPWO2015166986A1 (ja) 2017-04-20
RS61273B1 (sr) 2021-01-29
WO2015166986A1 (ja) 2015-11-05
DK3138555T3 (da) 2020-12-14

Similar Documents

Publication Publication Date Title
EP3161143C0 (en) PRODUCTION OF OLIGOSACCHARIDES
PL3322588T3 (pl) Rura wielowarstwowa i sposób jej wytwarzania
DK3453721T3 (da) Process of manufacture of annexin v
LT3237432T (lt) Baltymo gamyba
PL3102503T3 (pl) Kartusz oraz sposób wytwarzania kartusza
PL3102185T3 (pl) Nanozawiesina materiałów naturalnych i sposób jej wytwarzania
PL3091003T3 (pl) Pochodna 1,2‑naftochinonu i sposób jej przygotowania
GB201420309D0 (en) Elctrode Structure and method of manufacture thereof
PL3380241T3 (pl) Jednolita serologiczna pipeta i sposoby jej produkcji
HUE056799T2 (hu) Módszer specifikus természetes kapszaicinoidok mikrobiális elõállítására
PL3138555T3 (pl) Kompozycja liposomowa i sposób jej wytwarzania
PL3250042T3 (pl) Kompozycja, sposób, zastosowanie i wyrób
PL3206771T3 (pl) Sposób dostosowywania składu produktów chromatograficznych
HUE059378T2 (hu) Szigetelõfólia, valamint szigetelõfólia elõállítására szolgáló eljárás
PL3309149T3 (pl) Kryształ 6-bromo-3-hydroksy-2-pirazynokarboksamidu i sposób jego wytwarzania
HRP20181805T1 (hr) Postupak za proizvodnju poligvanidina
EP3527578A4 (en) NOVEL GLYCOSIDE COMPOUND AND PROCESS FOR PRODUCING THE SAME
FI20155387A7 (fi) Sterolien tuottaminen
PL3088617T3 (pl) Ściana z przejściem i sposób jej wytwarzania
PL3286011T3 (pl) Dokument zabezpieczony i sposób wytwarzania
LT3253772T (lt) Diosmino ruošimo būdas
PL3381938T3 (pl) Sposób zwiększania wydajności kolagenu i kolagen wytworzony przy jego użyciu
PL3536162T3 (pl) Pasza i sposób jej wytwarzania
PL3430105T3 (pl) Karbożelowe materiały anodowe i sposób ich wytwarzania
KR20180084948A (ko) 절연체 및 그 제조 방법